Kimberley Iris Hemelrijk

Kimberley Iris Hemelrijk

Auto-generated profile, based on publicly available information

Kimberley Iris Hemelrijk

Heart Center, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
ANAstrid van Nieuwkerk
Astrid van Nieuwkerk
HAHugo M. Aarts
Hugo M. Aarts
KHKimberley I. Hemelrijk
Kimberley I. Hemelrijk
CCCristobal Urbano Carrillo
Cristobal Urbano Carrillo
DTDidier Tchétché
Didier Tchétché
RDRonak Delewi
Ronak Delewi
Background: Cerebrovascular events remain one of the most devastating complications of transcatheter aortic valve implantation (TAVI). Data from real‐world contemporary cohorts on longitudinal trends and outcomes remain limited. The aim of this study was to assess incidence, temporal trends, predictors, and outcomes of cerebrovascular events following transfemoral TAVI. Methods and Results: The CENTER2 (Cerebrovascular Events in Patients Undergoing Transcatheter Aortic Valve Implantation With Balloon‐Expandable Valves Versus Self‐Expandable Valves 2) study includes patients undergoing TAVI between 2007 and 2022. The database contains pooled patient‐level data from 10 clinical studies. A total of 24 305 patients underwent transfemoral TAVI (mean age 81.5±6.7 years, 56% women, median Society of Thoracic Surgeon Predicted Risk of Mortality 4.9% [3.1%–8.5%]). Of these patients, 2.2% (n=534) experienced stroke in the first 30 days after TAVI, and 40 (0.4%) had a transient ischemic attack. Stroke rates remained stable during the treatment period (2007–2010: 2.1%, 2011–2014: 2.5%, 2015–2018: 2.1%, 2019–2022: 2.1%; P trend =0.28). Moreover, 30‐day cerebrovascular event rates were similar across Society of Thoracic Surgeon Predicted Risk of Mortality risk categories: 2.1% in low‐risk, 2.6% in intermediate‐risk, and 2.5% in high‐risk patients ( P =0.21). Mortality was higher in patients with 30‐day stroke than without at 30 days (20.3% versus 4.7%; odds ratio, 5.1 [95% CI, 4.1–6.5]; P <0.001) and at 1 year (44.1% versus 15.0%; hazard ratio, 3.5 [95% CI, 3.0–4.2]; P <0.001). One‐year mortality rates for stroke did not decline over time (2007–2010: 46.9%, 2011–2014: 46.0%, 2015–2018: 43.0%, 2019–2022: 39.1%; P trend =0.32). At 1 year, 7.0% of patients undergoing TAVI had a stroke. Conclusions: In 24 305 patients who underwent transfemoral TAVI, 30‐day cerebrovascular event incidence remained ≈ 2.2% between 2007 and 2022. Thirty‐day stroke rates were similar throughout Society of Thoracic Surgeon Predicted Risk of Mortality risk categories. Mortality rates after stroke remain high. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03588247.

14 February 2025 in eClinicalMedicine
Verified
Journal Article
Open access
ANAstrid C. van Nieuwkerk
Astrid C. van Nieuwkerk
KHKimberley I. Hemelrijk
Kimberley I. Hemelrijk
HAHugo M. Aarts
Hugo M. Aarts
ALAnna E. Leeuwis
Anna E. Leeuwis
CMCharles B.L.M. Majoie
Charles B.L.M. Majoie
RDRonak Delewi
Ronak Delewi
Approximately one-third of patients with symptomatic severe aortic valve stenosis scheduled for transcatheter aortic valve implantation (TAVI) have some degree of cognitive impairment. The effect of TAVI on cardiac output, cerebral blood flow (CBF), and cognitive functioning has not been systematically studied. CAPITA (NCT05481008) is a prospective longitudinal study assessing cerebral and cognitive outcomes in patients that underwent TAVI between August 2020 and October 2022. At baseline (<24 h before TAVI) and three-month follow-up, patients underwent echocardiography, brain magnetic resonance imaging (MRI), and multidomain neuropsychological assessment. Primary outcome measures were change in CBF (Δml/100 g/min on arterial spin labelling MRI) and change in global cognitive functioning (Δz-scores). Secondary outcomes included cardiac output (L/min), and white matter hyperintensities (mL, number). Differences were tested with paired t-test and associations were tested with linear mixed models. A total of 148 patients (80.5 ± 5.7 years, 43% female) underwent TAVI. Three months after TAVI, cardiac output increased from 5.9 ± 1.4 L/min to 6.3 ± 1.4 L/min (mean difference 0.37, 95% CI 0.12–0.62, p = 0.004). CBF increased from 52.2 ± 14.5 mL/100 g/min to 55.9 ± 17.7 mL/100 g/min (mean difference 3.8, 95% CI 1.15–6.36, p = 0.005). Global cognitive functioning also increased from 0.02 ± 0.52 to 0.15 ± 0.49 (mean difference 0.13, 95% CI 0.06–0.20, p < 0.001) with most prominent increase in patients with worst baseline cognitive functioning. Patients with cognitive decline (22%), had a higher volume of new in white matter hyperintensities than patients with stable or improved cognition (78%): 1.26 ± 2.96, vs 0.29 ± 0.45, vs 0.31 ± 0.91 mL (p = 0.06). In patients with severe symptomatic aortic valve stenosis undergoing TAVI, cardiac output, CBF, and cognitive functioning improved after three months. The Heart-Brain Connection crossroad consortium of the 10.13039/100018890 Dutch Cardiovascular Alliance . The Netherlands CardioVascular Research Initiative: 10.13039/100002129 Dutch Heart Foundation (CVON 2018-28 & 2012-06 Heart Brain Connection).

24 May 2026 in Atherosclerosis
Verified
Journal Article
Open access
KHKimberley Iris Hemelrijk
Kimberley Iris Hemelrijk
RDRonak Delewi
Ronak Delewi
RMRoxana Mehran
Roxana Mehran
SBS. Matthijs Boekholdt
S. Matthijs Boekholdt
Calcific aortic valve stenosis (CAVS) is the most common valvular heart disease requiring intervention. Progressive fibrocalcific thickening of the valve leaflets results in left ventricular outflow tract obstruction. Once symptoms emerge, CAVS is associated with high morbidity and mortality, contributing to over 100,000 deaths globally each year. The worldwide prevalence of CAVS is rising, affecting a 9.6 to 12.6 million people according to Global Disease Burden estimates, thereby becoming an increasingly public health burden. This narrative review summarizes current knowledge on the epidemiology, risk factors, pathophysiology, and disparities associated with CAVS. Age and congenital leaflet abnormalities are the most substantial risk factors for developing CAVS. Classical cardiovascular risk factors such as hypertension, dyslipidemia, obesity, and smoking increase disease burden, but also valve-specific risk factors such as lipoprotein(a) and valve calcification accelerate disease progression. Furthermore, we examine sex differences in valvular and myocardial remodeling, as well as sex-related disparities in diagnosis and treatment. Additionally, we explore racial and ethnic variations in disease epidemiology and management, acknowledging that significant disparities in the diagnosis and treatment of CAVS. The anticipated rise in disease burden due to an aging population and persistent cardiovascular risk factors underscores the need for comprehensive strategies. Currently, there are no targeted medical therapies proven to prevent onset or halt progression of these diseases. Primary intervention including aggressive risk factor modification is needed to effectively reduce future morbidity and mortality. Public health initiatives, lifestyle interventions, and policy measures to reduce disparities will play pivotal roles in addressing this health challenge.

19 May 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
KHKimberley Iris Hemelrijk
Kimberley Iris Hemelrijk
MNMatias R Mon Noboa
Matias R Mon Noboa
GTGabriela Tirado‐Conte
Gabriela Tirado‐Conte
TWToon Winkelman
Toon Winkelman
LALluís Asmarats
Lluís Asmarats
LNLuis Nombela
Luis Nombela
Background: Transcatheter aortic valve replacement (TAVR) has shown noninferiority to surgical aortic valve replacement (SAVR). However, patients with bicuspid aortic stenosis are often excluded from these studies. More insights between these procedures in this population is crucial for treatment selection. Methods: In this multicenter observational study, patients with bicuspid aortic stenosis undergoing TAVR or SAVR were analyzed using propensity score matching. The primary outcome was a composite of all‐cause mortality, stroke, rehospitalization, or valve dysfunction at 1 year. Results: A total of 997 patients with bicuspid aortic stenosis underwent TAVR or SAVR. In the matched cohort of 256 pairs, the median age was 75.0 years (interquartile range, 71.0–78.0), 234 (44.9%) were women, and the median EuroScore II was 1.83% (interquartile range, 1.34–2.86). One‐year cumulative incidence of the primary outcome was 15.0% in TAVR compared with 12.0% in SAVR (hazard ratio [HR], 1.35 [95% CI, 0.83–2.19], P =0.23). Mortality (4.3% versus 5.0%, P =0.72) and rehospitalization (4.8% versus 6.4%, P =0.45) were similar between groups. Although rates of valve dysfunction (2.9% versus 0.5%, P =0.06) and stroke (5.3% versus 2.3%, P =0.10) were numerically lower in the surgical group at 1 year, both the risk of stroke (subdistribution HR, 3.01, P =0.02) and valve dysfunction (subdistribution HR, 4.16, P =0.03) were significantly higher in the TAVR group at 2 years. Conclusions: TAVR in patients with bicuspid aortic stenosis showed a similar 1‐year primary outcome rate compared with SAVR, though TAVR exhibited higher rates of valve dysfunction and stroke. These findings underscore the need for randomized trials to define the optimal treatment strategy for this population.

15 March 2023 in JACC: Case Reports
Verified
Journal Article
Open access
KHKimberley Iris Hemelrijk
Kimberley Iris Hemelrijk
DFDaniel Faria
Daniel Faria
PSPablo Salinas
Pablo Salinas
JEJavier Escaned
Javier Escaned
Managing coronary saphenous vein graft failure has remained an unmet need since the inception of interventional cardiology. The present case constitutes an opportunity to revisit percutaneous strategies to treat saphenous vein graft failure, providing a travel though interventional strategies and showing a contemporary approach to this problem. (Level of Difficulty: Intermediate.).

3 November 2026 in Structural Heart
Verified
Journal Article
Open access
GBGijs M. Broeze
Gijs M. Broeze
KHKimberley I. Hemelrijk
Kimberley I. Hemelrijk
PJPilar Jimenez-Quevedo
Pilar Jimenez-Quevedo
DTDidier Tchétché
Didier Tchétché
FBFabio S. de Brito
Fabio S. de Brito
RDRonak Delewi
Ronak Delewi